Info@ThinkPinkRocks.org

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma.

Read More:
CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi’s sarcoma

Scroll to Top